Comparison
Semaglutid vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
910463-68-2
86168-78-7
Molecular weight
4113.6 g/mol
3358 g/mol
Half-life
165 h
0.2 h
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
5
3